Celyad–Horizon Discovery: shRNA technology, 201810– license excl to develop allogeneic CAR-T cell therapies |
2018-10-04 |
GenAhead Bio–ERS Genomics: CRISPR technology, 201810– license non-excl to CRISPR/Cas9 genome editing IP of ERS Genomics Ltd |
2018-10-04 |
Iqvia–United Kingdom (govt): clinical genomics, 201810– collab to develop integrated platform with clinical + genomics data with Genomics England |
2018-10-04 |
Arcis:Altos–SEVERAL: investment, 201810 financing round £1.25m of Arcis Biotechnology from existing + new investors |
2018-10-02 |
Arcis:Altos–SEVERAL: investment, 201810– crowd funding round targeting £0.5m of Arcis Biotechnology via Capital Cell |
2018-10-02 |
Evonetix–Magic Micro: DNA synthesis technology, 201810– collab developm of MEMS for DNA synthesis with LioniX Intl |
2018-10-01 |
Forbion–SEVERAL: investment, 201810 final close €360m of Forbion IV fund |
2018-10-01 |
Owlstone–Foxconn: investment, 201810 financing round totalling additional $35m incl new + co-investor Foxconn Technology Group |
2018-10-01 |
Owlstone–Horizons Ventures: investment, 201810 financing round totalling additional $35m incl existing + lead investor Horizons Ventures |
2018-10-01 |
Owlstone–SEVERAL: investment, 201810 financing round additional $35m (£27m) bringing total to $50m led by Horizons Ventures |
2018-10-01 |
Owlstone–Ventura Capital: investment, 201810 financing round totalling additional $35m incl new + co-investor Ventura Capital |
2018-10-01 |
VelosBio–Arix Bioscience: investment, 201810 financing round Series A totalling $58m incl $11m from new + co-lead investor Arix Bioscience |
2018-10-01 |
VelosBio–SEVERAL: investment, 201810 financing round Series A $58m co-led by new investors Arix Bioscience + Sofinnova Ventures |
2018-10-01 |
VelosBio–Sofinnova: investment, 201810 financing round Series A totalling $58m incl new + co-lead investor Sofinnova Ventures |
2018-10-01 |
Tusk Therapeutics–Roche: investment, 201809 acquisition for €70m cash + €585m milestones with some assets spun out into Black Belt Therapeutics |
2018-09-28 |
TTP Group–Battery Ventures: investment, 201810 acquisition €na of TTP Labtech from TTP Group by Battery Ventures |
2018-09-27 |
Nightstar Therapeutics–SEVERAL: investment, 201809 Public Offering $72m+$10.8m with 4m+600k ADS at $18/ADS |
2018-09-25 |
Histologix–Intelligent Tissue Group: investment, 201809 acquisition of Histologix Ltd by The Intelligent Tissue Group Ltd |
2018-09-20 |
Oxford Genetics–ERS Genomics: CRISPR technology, 201809– license non-excl for CRISPR modified cell lines extended to APAC region |
2018-09-20 |
Oxford VR–SEVERAL: investment, 201809 financing round £3.2m incl OSI + Univ Oxford + Force Over Mass et al |
2018-09-20 |
Thermo Fisher–ERS Genomics: CRISPR technology, 201809– license ww non-excl rights to products + tools + services for research from ERS Genomics |
2018-09-18 |
GamaMabs Pharma–Andrew Lloyd Associates: public relations, 201809 service existent by ALA |
2018-09-17 |
AstraZeneca–Horizon Discovery: genomic libraries, 201809– supply adoption of Edit-R crRNA libraries for funcitonal genomics discovery platform by AZ |
2018-09-14 |
Applied Microarrays–Novacyt: DNA microarrays, 201809– €na collab developm probes for customised SNP microarrys by Primerdesign |
2018-09-13 |
Cell Medica–United Kingdom (govt): cell therapy manfucturing, 201809 supply existent Cell Medica uses CGT Catapult manufacturing centre in Stevenage |
2018-09-11 |
Freeline Therapeutics–United Kingdom (govt): gene therapy manfucturing, 201809 supply Freeline uses CGT Catapult manufacturing centre in Stevenage |
2018-09-11 |
Optibrium–Intellegens: drug discovery software, 201809– collab providing Optibrium clients access to Intellegens’ Alchemite AI technology |
2018-09-11 |
Arecor–Albion Ventures: investment, 201809 financing round totalling £6m incl co-lead investor Albion Capital |
2018-09-10 |
Arecor–Calculus Capital: investment, 201809 financing round totalling £6m incl co-lead investor Calculus Capital |
2018-09-10 |
Arecor–Downing: investment, 201809 financing round totalling £6m incl co-lead investor Downging Ventures |
2018-09-10 |
Arecor–SEVERAL: investment, 201809 financing round £6m co-led by Calculus Capital + Downing Ventures + Albion Capital |
2018-09-10 |
Merck (DE)–AstraZeneca: digital pathology, 201809– collab multi-year partnership with Definiens using TissuePhenomics for biomarker quantification |
2018-09-10 |
Novate Medical–BTG: investment, 201809 acquisition $20m cash upfront + $130m milestones of Novate Medical Ltd by BTG plc |
2018-09-07 |
Adaptimmune–Matrix Capital Manamagent: investment, 201809 registered direct offering totalling $100m incl existing investor Matrix Capital |
2018-09-05 |
Adaptimmune–New Enterprise Associates: investment, 201809 registered direct offering totalling $100m incl existing investor NEA 16 LP + NEA 14 LP |
2018-09-05 |
Adaptimmune–SEVERAL: investment, 201809 registered direct offering $100m of 10m ADSs at $10/ADS to Matrix Capital + NEA + Syncona |
2018-09-05 |
Adaptimmune–Wellcome Trust: investment, 201809 registered direct offering totalling $100m incl new investor Syncona Portfolio Ltd |
2018-09-05 |
Optibrium–Enamine: chemical compound libraries, 201809– collab free access to EnamineStore database for StarDrop users |
2018-09-04 |
Evox Therapeutics–Alphabet: investment, 201809 financing round Series B totalling £35.5m incl new investor GV |
2018-09-03 |
Evox Therapeutics–Borealis Ventures: investment, 201809 financing round Series B totalling £35.5m incl new investor Borealis Ventures |
2018-09-03 |
Evox Therapeutics–Cowen: investment, 201809 financing round Series B totalling £35.5m incl new investor Cowen Healthcare Investments |
2018-09-03 |
Evox Therapeutics–OTHER: investment, 201809 financing round Series B totalling £35.5m incl small number of private investors |
2018-09-03 |
Evox Therapeutics–Panacea Venture: investment, 201809 financing round Series B totalling £35.5m incl new investor PHV |
2018-09-03 |
Evox Therapeutics–Redmile Group: investment, 201809 financing round Series B totalling £35.5m incl new + lead investor Redmile Group |
2018-09-03 |
Evox Therapeutics–SEVERAL: investment, 201809 financing round Series B £35.5m led by Redmile Group |
2018-09-03 |
Evox Therapeutics–Univ Oxford: investment, 201809 financing round Series B totalling £35.5m incl existing investors OSI + Oxford Univ |
2018-09-03 |
Genomics Medicine Ireland–Univ Cambridge: genomics, 201808– collab using 15000 DNA-extracted MS samples from biobank of Prof Sawcer |
2018-08-30 |
Genomics plc–FTI Consulting: public relations, 201808 service existent by FTI Consulting |
2018-08-30 |
Genomics plc–Invesco: investment, 201808 financing round Series B totalling £25m incl existing + co-investor Invesco Perpetual |
2018-08-30 |
Genomics plc–IP Group: investment, 201808 financing round Series B totalling £25m incl existing + co-investor IP Group |
2018-08-30 |
Genomics plc–Lansdowne Partners: investment, 201808 financing round Series B totalling £25m incl existing + co-investor Lansdowne Partners |
2018-08-30 |
Genomics plc–SEVERAL: investment, 201808 financing round Series B £25m led by Vertex + incl IP Group + Woodford et al |
2018-08-30 |
Genomics plc–Tanarra: investment, 201808 financing round Series B totalling £25m incl co-investor Tamorer Pty Ltd |
2018-08-30 |
Genomics plc–Univ Oxford: investment, 201808 financing round Series B totalling £25m incl co-investor Oxford Sciences Innovation |
2018-08-30 |
Genomics plc–Vertex: investment, 201808 financing round Series B totalling £25m incl lead investor Vertex in connection with collab |
2018-08-30 |
Genomics plc–Woodford Investment: investment, 201808 financing round Series B totalling £25m incl existing + co-investor Woodford Investment |
2018-08-30 |
Lunaphore–SEVERAL: investment, 201808 financing round Series B CHF5.3m from existing + new investors |
2018-08-30 |
Vertex–Genomics plc: bioinformatics, 201808– collab expansion using human genetics + data science for target discovery + personalised medicine |
2018-08-30 |
Kandy Therapeutics–Advent Life Sciences: investment, 201808 financing round Series C totalling £25m incl existing investor Advent Life Sciences |
2018-08-29 |
Kandy Therapeutics–Forbion: investment, 201808 financing round Series C totalling £25m incl existing investor Forbion Capital Partners |
2018-08-29 |
Kandy Therapeutics–Fountain Healthcare Partners: investment, 201808 financing round Series C totalling £25m incl existing investor Fountain HCP |
2018-08-29 |
Kandy Therapeutics–Longitude Capital: investment, 201808 financing round Series C totalling £25m incl new investor Longitude Capital |
2018-08-29 |
Kandy Therapeutics–OrbiMed: investment, 201808 financing round Series C totalling £25m incl existing investor OrbiMed |
2018-08-29 |
Kandy Therapeutics–SEVERAL: investment, 201808 financing round Series C £25m from Longitude Capital + Advent LS + Fountain HCP + Forbion + OrbiMed |
2018-08-29 |
Nebula Genomics–Heartbeat Labs: investment, 201808 seed financing round totalling $4.3m incl Heartbeat Labs |
2018-08-29 |
Nebula Genomics–Hikma: investment, 201808 seed financing round totalling $4.3m incl Hikma Ventures |
2018-08-29 |
Nebula Genomics–SEVERAL: investment, 201808 seed financing round $4.3m from ten leading tech + biotech VCs |
2018-08-29 |
Congenica–Instinctif Partners: public relations, 201808 service existent by Instinctif |
2018-08-28 |
Thermo Fisher–BioStrata: public relations, 201808 service existent by BioStrata |
2018-08-27 |
SolasCure–Brain Biotech: investment, 201808–202108 financing round Series A totalling £15m incl lead investor Brain Biotech AG |
2018-08-22 |
SolasCure–BRAIN Biotech: wound care product, 201808– license IP for Aurase enzyme + supply of enzymatic active ingredient by BRAIN to SolasCure |
2018-08-22 |
SolasCure–SEVERAL: investment, 201808–202108 financing round Series A £15m led by Brain Biotech AG |
2018-08-22 |
HackScience–SEVERAL: investment, 201808 seed financing round $1.8m |
2018-08-20 |
Ziylo–Novo Group: investment, 201808 acquisition 100% for up to $800m in upfront + milestone payments by Novo Nordisk |
2018-08-17 |
Abzena–Welsh Carson Anderson & Stowe: investment, 201808– recommended cash offer 16p/share valueing Abzena at £34.4m by WCAS XII-Astra LP |
2018-08-16 |
Blueberry Therapeutics–Bryan Garnier: financial services, 201808 supply service financial advisor with regard to £10m Series B financing round |
2018-08-14 |
Blueberry Therapeutics–China Medial System: investment, 201808 financing round Series B totalling £10m incl China Medical Venture Investment (HK) Ltd |
2018-08-14 |
Blueberry Therapeutics–Onyx Health: public relations, 201808 service existent by Onyx Health PR |
2018-08-14 |
Blueberry Therapeutics–PERSON: investment, 201808 financing round Series B totalling £10m incl investor A&B (HK) Ltd |
2018-08-14 |
Blueberry Therapeutics–SEVERAL: investment, 201808 financing round Series B £10m from China Medical Venture Investment + A&B (HK) |
2018-08-14 |
Blueberry Therapeutics–Slater Heelis: legal services, 201808 supply service legal advisor with regard to £10m Series B financing round |
2018-08-14 |
Orchard Therapeutics–SEVERAL: investment, 201808 financing round Series C $150m led by Deerfield Management |
2018-08-13 |
Artios Pharma–AbbVie: investment, 201808 financing round Series B totalling $84m incl existing + co-investor AbbVie Ventures |
2018-08-10 |
Artios Pharma–Andera Partners: investment, 201808 financing round Series B totalling $84m (£65m) incl new + lead investors Andera Partners + LSP |
2018-08-10 |
Artios Pharma–Arix Bioscience: investment, 201808 financing round Series B totalling $84m incl existing + co-investor Arix Bioscience |
2018-08-10 |
Artios Pharma–IP Group: investment, 201808 financing round Series B totalling $84m incl existing + co-investor IP Group |
2018-08-10 |
Artios Pharma–Life Sciences Partners: investment, 201808 financing round Series B totalling $84m incl new + lead investors Andera Partners + LSP |
2018-08-10 |
Artios Pharma–Merck (DE): investment, 201808 financing round Series B totalling $84m incl existing + co-investor M Ventures |
2018-08-10 |
Artios Pharma–Novartis: investment, 201808 financing round Series B totalling $84m incl new + co-investor Novartis Venture Fund |
2018-08-10 |
Artios Pharma–Optimum Strategic Communications: public relations, 201808 service existent by Optimum |
2018-08-10 |
Artios Pharma–Pfizer: investment, 201808 financing round Series B totalling $84m incl new + co-investor Pfizer Ventures |
2018-08-10 |
Artios Pharma–SEVERAL: investment, 201808 financing round Series B $84m (£65m) led by new investors Andera Partners + LSP |
2018-08-10 |
Artios Pharma–SV Health Investors: investment, 201808 financing round Series B totalling $84m incl existing + co-investor SV |
2018-08-10 |
Quethera–Astellas: investment, 201808 acquisition for up to £85m in upfront + milestones payment |
2018-08-10 |
Vernalis–Ligand: investment, 201808– recommended cash takeover offer £32.8m with £0.062/share ANNOUNCED |
2018-08-09 |
Pharmaxis–Arix Bioscience: investment, 201808– primary placing totalling A$24m incl A$14.2m in two tranches from lead investor Arix Bioscience |
2018-08-06 |
Pharmaxis–SEVERAL: investment, 201808– primary placing A$24m in two tranches led by Arix Bioscience |
2018-08-06 |
United Kingdom (govt)–Bruker: NMR technology, 201808 supply £20m NMR technology to 8 UK universities funded by EPSRC + BBSRC + MRC +NERC |
2018-08-06 |
Univ Birmingham–Bruker: NMR spectrometer, 201808 supply 1GHz NMR spectrometer |
2018-08-06 |
Univ Warwick–Bruker: NMR spectrometer, 201808 supply Avance 1.0 GHz solid-state NMR spectrometer |
2018-08-06 |